Overexpression of MDM2 can impair wild-type TP53 function in two ways by binding to the transactivation site of TP53 in the nucleus or by targeting TP53 for ubiquitination and degradation in the cytoplasm, and linked with low levels of TP53 immunostaining in human breast cancers[34]. This evidence concerns the gene MDM2 and breast cancer.